<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the short-term effectiveness and tolerance of rituximab in patients with systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> erythematous and distinct clinical manifestations </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Thirteen patients were studied </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab (RTX) was indicated for refractory <z:hpo ids='HP_0000123'>nephritis</z:hpo> in 6 patients, severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in 5, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in 1 and peritoneal <z:hpo ids='HP_0002633'>vasculitis</z:hpo> associated with <z:hpo ids='HP_0000123'>nephritis</z:hpo> in 1 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received 4 weekly doses of 375 mg/m(2) of RTX </plain></SENT>
<SENT sid="4" pm="."><plain>The mean length of follow-up was 12Â±8.5 months </plain></SENT>
<SENT sid="5" pm="."><plain>Response was favorable in 9 patients: 3 with <z:hpo ids='HP_0000123'>nephritis</z:hpo>, 5 with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and 1 with peritoneal <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and <z:hpo ids='HP_0000123'>nephritis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The mean SLE disease activity index decreased from 11 to 6.5 points </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> recurred in 2 patients, who responded well to retreatment </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The present study demonstrates that RTX is safe and effective as short-term therapy for distinct clinical manifestations associated with SLE </plain></SENT>
</text></document>